MC38 HuSyngeneic Screen

ENROLLMENT OPEN NOW THROUGH November 30th

• B6 mice expressing human PD-1 & human CTLA4.
• MC38 cell line expressing human PD-L1.

MC38 huSyngeneic is a transgenic syngeneic platform which allows for the use of human therapeutics targeting PD-1, PD-L1 and/or CTLA4.

Participate in the Champions Oncology MC38 huSyngeneic screen for a more biologically relevant MC38 model.


Enrollment in this study is now open on a first-come-first-served basis.


Sample data detailing responses to Keytruda is shown below:

The details on Champions’ MC38 huSyngeneic screen are discussed below:

Full knock-out of murine targets
Endogenous expression of human targets
The model has been characterized for Keytruda Response
FREE Vehicle response data
50% off Keytruda data
Limited enrollment available on a first-come-first-served basis

Enrollment open now through November 30th